BioCryst Pharmaceuticals Stock BCRX
BioCryst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare diseases, with hereditary angioedema (HAE) as its primary therapeutic area. BioCryst Pharmaceuticals stock (BCRX): Quarterly and annual results since 2023 from Quarterly Report and SEC filings: revenue, earnings, balance sheet, cash flow and management guidance, every figure with its source. As of 08/2026, quarterly reporting. Stock analysis by NadirAlpha. BioCryst Pharmaceuticals stock (BCRX): listed on Nasdaq. NadirAlpha has evaluated 52 original documents, cross-checked every figure automatically and linked each to its source; sources as of 08/2026. Revenue Q2 2026: USD 218 million (+34% year on year). Latest reported (Q2 2026): Total revenue growth (y-o-y), ORLADEYO revenue growth (y-o-y), ORLADEYO global peak market. Latest reading: Operating income doubled, Net income doubled, Revenue accelerating, Cash flow inflection, Guidance raised, Strategic pivot.
AI-generated report · not investment advice · figures extracted automatically; please verify against the linked original more
BioCryst Pharmaceuticals Current Status
Summary of the most recent reporting period of BioCryst Pharmaceuticals (Q2 2026): core figures, drivers and management statements, every figure with a source number. NadirAlpha methodology
Assessment by NadirAlpha, as of Q2 2026.
“Building on this momentum, we remain focused on cost discipline while directing our capital and energy toward opportunities where we can have the greatest impact. This positions BioCryst exceptionally well to continue delivering growth, strong profitability, and lasting value for patients and their families as well as our shareholders.”
“We were pleased to deliver strong revenue growth and positive free cash flow again in the second quarter, reflecting our continued focus on expanding the reach of ORLADEYO while advancing our prioritized pipeline programs. We are especially excited to have begun shipments of the ORLADEYO oral pellet formulation, an important milestone for children living with hereditary angioedema, and we are fully committed to making the launch a success.”
BioCryst Pharmaceuticals Stock: Key Figures ($ million)
NadirAlpha shows fiscal years, half-years and quarters of BioCryst Pharmaceuticals one below the other, most recently Q2 2026; every figure is clickable and leads to raw value, location and source. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
All figures serve only to support your own investment decision and are not a recommendation; the company's original reports are authoritative.
Fiscal years
| Period | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | OCF | Source |
|---|---|---|---|---|---|---|---|
| FY2025 | 874.8 | 341 | 213.6 | 263.9 | 1.21 | 347.4 | 29 |
| FY2024 | 450.7 | -2.5 | 64.2 | -88.9 | -0.43 | -52 | 21 |
| FY2023 | 331.4 | -103.7 | -48.09 | -226.5 | -1.18 | -95.1 | 10 |
Quarters
| Period | Published | Revenue | Op. income | Op. income (adj.) | Net income | EPS ($) | FCF | Cash | Net Debt | Source |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2* | 2026-08-05 | 218.2 | 98.5 | 113.2 | 78.4 | 0.30 | 104.1 | 155 | 240.4 | 34 |
| 2026-Q1* | 2026-05-06 | 156.4 | -701.6 | 0.05 | -721.8 | -2.98 | -62.2 | 171.6 | 223.6 | 32 |
| 2025-Q4* | 2026-01-12 | 406.6 | 260.4 | 58.4 | 245.8 | 1.13*≈ | 291.2 | 89.7 | -89.7 | 29 |
| 2025-Q3* | 2025-11-03 | 159.4 | 29.6 | 51.7 | 12.9 | 0.06 | 40.3 | 84.1 | 110.3 | 27 |
| 2025-Q2* | 2025-08-04 | 163.4 | 29.8 | 60.9 | 5.1 | 0.02 | 41.1 | 88 | 154.8 | 24 |
| 2025-Q1* | 2025-05-05 | 145.5 | 21.2 | 42.6~ | 0 | 0.00 | -27.7 | 105.2 | 210.2 | 22 |
| 2024-Q4* | 2025-01-10 | 131.5 | -4.5 | 18.2 | -26.8 | -0.13*≈ | -5.9 | 104.7 | 210.2 | 19 |
| 2024-Q3* | 2024-11-04 | 117.1 | 7.7 | 24.9 | -14 | -0.07 | 8.2 | 96.8 | 217.5 | 17 |
| 2024-Q2* | 2024-08-05 | 109.3 | 8.8 | 21.9 | -12.7 | -0.06 | -1.5 | 78.4 | 235.4 | 15 |
| 2024-Q1* | 2024-05-06 | 92.8 | -14.5 | -0.8 | -35.4 | -0.17 | -53.9 | 84.3 | 224.2 | 13 |
| 2023-Q4* | 2024-01-08 | 93.4 | -42.7 | -26.2 | -61.7 | -0.32*≈ | -9.5 | 110.6 | 192.6 | 10 |
| 2023-Q3* | 2023-11-02 | 86.7 | -11.9 | 0.4 | -36.1 | -0.19 | -20.9 | 150.9 | 147.1 | 8 |
| 2023-Q2* | 2023-08-03 | 82.5 | -20.7 | -7.9 | -75.3 | -0.40 | -19.3 | 146.2 | 147 | 6 |
| 2023-Q1* | 2023-05-03 | 68.8 | -28.4 | – | -53.3 | -0.28 | -47.7 | 155.1 | 77.4 | 4 |
BioCryst Pharmaceuticals Balance Sheet & Cash Flow ($ million)
Point-in-time balance sheet items of BioCryst Pharmaceuticals (cash, financial debt) and cash flow items per fiscal year, half-year and quarter, derived values with their formula in the popover. NadirAlpha extracts all values automatically from the filings; errors are possible; please verify decision-relevant figures yourself by clicking through to the linked original. NadirAlpha methodology
Fiscal years
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| FY2025 | 2026-02-26 | 89.7 | 0 | -89.7 | 1.4 | 347.4 | 2.5 | 344.9 | 30 |
| FY2024 | 2025-02-25 | 104.7 | 314.9 | 210.2 | 1.2 | -52 | 1.1 | -53.1 | 21 |
| FY2023 | 2024-02-27 | 110.6 | 303.2 | 192.6 | 1.7 | -95.1 | 2.2 | -97.3 | 12 |
Quarters
| Period | Published | Cash | Debt | Net Debt | D&A | OCF | Capex | FCF | Source |
|---|---|---|---|---|---|---|---|---|---|
| 2026-Q2 | 2026-08-05 | 155 | 395.4 | 240.4 | 0.5 | 104.3 | 0.2 | 104.1 | 34 |
| 2026-Q1 | 2026-05-06 | 171.6 | 395.2 | 223.6 | 1.1 | -61.8 | 0.4 | -62.2 | 32 |
| 2025-Q4 | 2026-02-26 | 89.7 | 0 | -89.7 | 0.4 | 292 | 0.8 | 291.2 | 30 |
| 2025-Q3 | 2025-11-03 | 84.1 | 194.4 | 110.3 | 0.3 | 41.6 | 1.3 | 40.3 | 27 |
| 2025-Q2 | 2025-08-05 | 88 | 242.8 | 154.8 | 0.3 | 41.3 | 0.2 | 41.1 | 25 |
| 2025-Q1 | 2025-05-06 | 105.2 | 315.4 | 210.2 | 0.3 | -27.5 | 0.1 | -27.7 | 23 |
| 2024-Q4 | 2026-02-26 | 104.7 | 314.9 | 210.2 | 0.3 | -5.2 | 0.7 | -5.9 | 30 |
| 2024-Q3 | 2024-11-04 | 96.8 | 314.3 | 217.5 | 0.3 | 8.2 | 0.1 | 8.2 | 17 |
| 2024-Q2 | 2024-08-05 | 78.4 | 313.8 | 235.4 | 0.3 | -1.4 | 0.2 | -1.5 | 15 |
| 2024-Q1 | 2024-05-07 | 84.3 | 308.5 | 224.2 | 0.3 | -53.7 | 0.2 | -53.9 | 14 |
| 2023-Q4 | 2025-02-24 | 110.6 | 303.2 | 192.6 | 0.4 | -8.9 | 0.6 | -9.5 | 20 |
| 2023-Q3 | 2023-11-08 | 150.9 | 298 | 147.1 | 0.4 | -19.9 | 1 | -20.9 | 9 |
| 2023-Q2 | 2023-08-07 | 146.2 | 293.2 | 147 | 0.4 | -18.8 | 0.5 | -19.3 | 7 |
| 2023-Q1 | 2023-05-08 | 155.1 | 232.5 | 77.4 | 0.4 | -47.5 | 0.2 | -47.7 | 5 |
BioCryst Pharmaceuticals Guidance Tracking (latest per metric/period · 11/20)
NadirAlpha records 20 guidance statements of BioCryst Pharmaceuticals neutrally: annual and quarterly targets, direction of change and outcome as a dot with legend, with no estimate of our own. NadirAlpha methodology
Actuals: revenue in $m
Direction: confirmedcutinitiatedraised Verdict: beatpending
| For period | Guided on | Metric | Guided | Actual | Verdict | Direction | Source |
|---|---|---|---|---|---|---|---|
| FY2026 | 2026-08-05 | Revenue | 690–715 | – | 35 | ||
| FY2026 | 2026-08-05 | OpEx (non-GAAP) | 420–440 | – | 35 | ||
| FY2026 | 2026-05-06 | ORLADEYO net revenue | 625–645 | – | 35 | ||
| FY2026 | 2026-01-12 | ORLADEYO revenue | 625–645 | – | 31 | ||
| FY2026 | 2024-02-26 | EPS (GAAP) | positive | – | 11 | ||
| FY2025 | 2025-11-03 | OpEx (non-GAAP) | 430–440 | – | – | 27 | |
| FY2025 | 2025-11-03 | ORLADEYO net revenue | 590–600 | – | – | 27 | |
| FY2025 | 2025-08-04 | Full year 2025 global net ORLADEYO revenue | 580–600 | – | – | 24 | |
| FY2025 | 2025-05-05 | OpEx (GAAP) | 440–450 | – | – | 22 | |
| FY2025 | 2025-02-24 | Revenue | 560–575 | 874.8 | 20 | ||
| FY2025 | 2025-01-10 | Total revenue (including RAPIVAB) | 540–560 | – | – | 19 | |
| FY2024 | 2024-11-04 | OpEx (GAAP) | 380–390 | – | – | 17 | |
| FY2024 | 2024-11-04 | ORLADEYO net revenue | 430–435 | – | – | 17 | |
| FY2024 | 2024-11-04 | Total product revenue | 443–448 | – | – | 17 | |
| FY2024 | 2024-05-06 | ORLADEYO revenue | 390–400 | – | – | 13 | |
| FY2023 | 2023-11-02 | ORLADEYO revenue | 320 | – | – | 8 | |
| FY2023 | 2023-08-03 | OpEx (GAAP) | ~375 | – | – | 6 | |
| FY2023 | 2023-02-21 | ORLADEYO global net revenue | 320 | – | – | 2 | |
| FY2023 | 2023-01-09 | ORLADEYO net revenue | 320 | – | – | 6 | |
| 2023-Q1 | 2023-02-27 | ORLADEYO net revenue | 4 | – | – | 3 |
BioCryst Pharmaceuticals Stock: Price & Chart
Interactive price chart of BioCryst Pharmaceuticals stock (TradingView) and the trend of key figures from the core tables; the chart loads only after a click and then connects to TradingView. NadirAlpha methodology
Daily candles with news and earnings markers. Loads only on click.
BioCryst Pharmaceuticals Event Timeline
What happened at BioCryst Pharmaceuticals since 2023: events from the filings, grouped by quarter, with the source date and a clickable source number. NadirAlpha methodology
2026 · 10 events
Total revenues 218.2 million, up 34% year-over-year, including $55.7 million from navenibart licensing agreement with Neopharmed Gentili recognized in Q2 35
Full year 2026 total revenue guidance raised to $690 million to $715 million; ORLADEYO revenue guidance maintained at $625 million to $645 million 35
Board approved Birmingham Closure Plan in June 2026 to discontinue internal discovery programs and close Discovery Center of Excellence by end of 2026 34
Operating income more than doubled YoY (29.8 to USD 98.5 million, +231%). 34
Operating cash flow reached USD 104.3 million vs USD 41.3 million in 2025-Q2 (×2.5). 34
“We began 2026 with continued strong execution across our business, led by sustained growth of ORLADEYO and solid progress across our pipeline. ORLADEYO continues to grow because its differentiated oral profile and high level of attack control meet the needs of an increasing number of people living with hereditary angioedema. At the same time, we remain on track with enrollment in our navenibart and BCX17725 pipeline programs. We are also pleased to partner again with Neopharmed Gentili for European rights to navenibart. This progress underscores our strategy to focus on rare diseases where we have deep expertise, execute efficiently, and allocate capital thoughtfully to drive sustainable value for patients and shareholders.”
Non-cash acquired in-process R&D charge of $697.8 million for navenibart from Astria transaction produced Q1 operating loss of 701.6 million 33
$400.0 million term loan entered with Blackstone on January 23, 2026 to fund Astria acquisition, maturing January 23, 2031 32
Acquisition of Astria Therapeutics completed on January 23, 2026, adding navenibart (Phase 3 HAE monoclonal antibody) and STAR-0310 (Phase 1 OX40 antagonist for atopic dermatitis) to pipeline 32
2025 · 18 events
“2025 was a transformative year for BioCryst. Continued strong demand for ORLADEYO and outstanding patient outcomes have solidified its position as the leading oral, once-daily prophylaxis treatment for HAE. The successful sale of our European ORLADEYO business further strengthened our financial position, and the proposed acquisition of Astria marks an exciting step toward expanding our impact for HAE patients. With our advancing pipeline, flexibility to continue pursuing value-creating business development opportunities, and dedication of our exceptional team, we are confident in our ability to deliver innovative treatments for rare disease patients and drive sustainable growth well into the future.”
Net income turned positive for the first time after 2 negative fiscal years (-88.9 to +USD 263.9 million). 30
“2025 was fundamentally transformative for BioCryst. We achieved full-year profitability for the first time in the company's history, driven by strong commercial execution that delivered the highest level of new patient prescriptions in the U.S. since the initial launch of ORLADEYO, even as the treatment landscape continued to evolve. We also advanced key business development initiatives that streamlined our operations and further strengthened our leadership position in hereditary angioedema. We entered 2026 with strong momentum, completing the acquisition of Astria Therapeutics to grow our HAE portfolio to meet the needs of more patients, while adding to our long-term growth trajectory well into the next decade.”
FY2025 GAAP operating income $341.0M (includes $243.3M one-time license revenue from European ORLADEYO divestiture) and non-GAAP operating income $214.2M; first full-year profitability in company history (31)
FY2025 ORLADEYO net revenue $601.8M, +38% year-over-year; excluding European business divested October 1, 2025, comparable growth was +43% (31)
FDA approved ORLADEYO oral pellets for pediatric patients with HAE aged 2 to under 12 years in December 2025 (31)
Net debt position flipped (+110.3 to -USD 89.7 million vs 2025-Q3). 30
“It has been an incredible honor to lead the employees of BioCryst over these past nearly 19 years. I couldn't be more confident in the exceptional team we have built and am excited to see them take BioCryst forward and continue to deliver innovative treatments for patients living with rare diseases.”
European ORLADEYO business sale to Neopharmed completed October 1, 2025 for $250M; Pharmakon loan fully retired October 8, 2025 using $198.7M of proceeds; pro forma cash reached $294M (27)
FY2025 ORLADEYO revenue guidance raised to $590-600M; non-GAAP operating expense guidance lowered to $430-440M (27)
Definitive merger agreement signed with Astria Therapeutics on October 14, 2025, adding navenibart monoclonal antibody inhibitor to HAE portfolio; transaction financed by $550M Blackstone credit facility, expected to close Q1 2026 (27)
Operating income more than doubled YoY (7.7 to USD 29.6 million, +284%). 27
Operating cash flow reached USD 41.6 million vs USD 8.2 million in 2024-Q3 (×5.1). 27
“The financial performance this quarter is the best in the company's history resulting from better-than-expected revenue growth and very meaningful operating profit. In the fifth year since approval, ORLADEYO revenue and demand have never been stronger, and this is driven by outstanding execution and increasing confidence in the product. Our accelerating operating profit and the sale of our European ORLADEYO business strengthen our financial position to deliver even greater value, and our pipeline remains on track for initial data later this year in two clinical programs.”
Entered stock purchase agreement to sell European ORLADEYO business to Neopharmed Gentili S.p.A. for $250M cash plus up to $14M in revenue milestones; proceeds earmarked to retire remaining Pharmakon term debt (25)
FDA accepted NDA for ORLADEYO oral granules for children aged 2 to 11 with HAE under priority review; PDUFA goal date December 12, 2025 (25)
Operating income more than doubled YoY (8.8 to USD 29.8 million, +239%). 25
ORLADEYO Q2 net revenue $156.8M, +45% year-over-year; new patient prescriptions highest ever in a single quarter, exceeding Q1 2025 launch-quarter prescriptions by over 10% (24)
“We started 2025 with another quarter of outstanding performance. ORLADEYO revenue growth was driven by moving ORLADEYO patients from free drug to paid at a much faster rate than we expected, resulting in a substantial increase to our annual guidance as we also move closer to peak sales of $1 billion. This increased financial strength accelerates our path to profitability and enables us to start paying down our debt, while continuing to invest in and advance our pipeline.”
Q1 operating income improved to $21.2M from operating loss of $14.5M in Q1 2024; company accelerated full-year profitability target by one year to 2025 from prior guidance of 2026 (22)
ORLADEYO net revenue +51% year-over-year to $134.2M, driven by accelerated conversion of patients from free drug to paid prescriptions and volume growth (22)
FY2025 ORLADEYO revenue guidance raised to $580-600M from prior range of $535-550M (22)
2024 · 15 events
“2024 was a year of outstanding execution for the company on multiple fronts and it is exciting to carry this momentum into 2025. We had another year of exceptional ORLADEYO revenue growth moving us significantly closer to peak sales of $1 billion, and we did this while driving the company toward profitability in the near-term. We are excited that this year we expect to submit a new drug application to expand the ORLADEYO label to children under age 12 and to be in patient studies in two new clinical programs (BCX17725 and avoralstat)”
“We ended 2024 with the strongest execution and performance in the company's history, and this year is off to a fantastic start, with ORLADEYO revenue already exceeding our initial expectations, the first clinical data from both the BCX17725 and avoralstat programs, and our pediatric label expansion for ORLADEYO anticipated later this year”
Operating cash flow turned positive on a half-year basis (2024-H1: -55.1 to 2024-H2: +USD 3.0 million, aggregated from reported quarters where needed). 30
Non-GAAP operating profit of $62.9M for FY2024 vs. operating losses in prior year; GAAP operating loss narrowed to $2.5M from $103.7M in 2023 20
ORLADEYO full-year net revenue +34% to $437.7M; total FY2024 revenue $450.7M, +36% YoY 20
2025 ORLADEYO revenue guidance raised to $535-$550M from prior $515-$535M; 2025 total revenue guidance raised to $560-$575M from $540-$560M 20
“Our third quarter performance continues to build on the outstanding year we are having, with significant revenue growth, strong patient demand, pipeline advancement and operating profitability in the quarter. As we look ahead, we see robust and durable revenue growth, new opportunities for younger children to benefit from ORLADEYO, and data readouts from BCX17725 in Netherton syndrome and avoralstat in DME, all while moving closer to sustainable profitability.”
BCX17725 (KLK5 inhibitor for Netherton syndrome) advanced into Phase 1 clinical trial with first participant enrolled in October 2024; initial data expected in 2025 18
Full-year 2024 ORLADEYO guidance narrowed to top end at $430-$435M from prior $420-$435M; total product revenue guidance introduced at $443-$448M based on additional RAPIVAB revenue 17
“The first half of 2024 has been outstanding for BioCryst due to the success we are having in the marketplace with ORLADEYO. As a result, we are increasing our full year guidance for ORLADEYO, advancing multiple programs toward the clinic in the next 18 months and moving the company closer to profitability.”
GAAP operating profit of $8.8M in Q2 2024 compared to operating loss of $20.7M in Q2 2023, reflecting lower R&D expenses following BCX10013 and BCX9930 program discontinuations 15
ORLADEYO net revenue +34% YoY to $108.3M in Q2 2024; ex-U.S. revenue +51% YoY, representing 11% of global ORLADEYO net revenues 15
Full-year 2024 ORLADEYO revenue guidance raised to $420-$435M from prior $390-$400M 15
EBITDA turned positive for the first time after 17 negative periods (-14.2 to +USD 9.1 million). 15
“We are off to a fantastic start to the year with outstanding ORLADEYO revenue growth and our prioritized pipeline programs advancing on schedule. We are focused on continuing this momentum as we see strong patient demand for ORLADEYO and more pipeline programs advancing into the clinic, starting later this year”
Company reduced R&D organization size and postponed planned capital expenditures at Discovery Center in Alabama in January 2024 to accelerate path to profitability 14
ORLADEYO net revenue +30% YoY to $88.9M in Q1 2024, driven by accelerated patient reauthorization from free drug to paid drug and new prescription growth 13
Company guided to full-year 2024 operating profit (excluding non-cash stock compensation) and positive cash flow in second half of 2025 13
FY2023 ORLADEYO net revenue reached $326.0M, +30% year-over-year; total revenues $331.4M versus $270.8M in 2022 12
2023 · 16 events
“The impressive growth we are seeing with ORLADEYO has put us in a position to accelerate our path to profitability while continuing to invest in our diverse pipeline of first-in-class or best-in-class molecules that we believe will deliver our next marketed product”
“After three years on the market, ORLADEYO continues on a steady growth trajectory to achieve $1 billion at peak. This commercial success, alongside our proven discovery platform that is producing additional first-in-class or best-in-class molecules, uniquely positions BioCryst to achieve financial independence from the capital markets and accelerate our path to profitability.”
ORLADEYO approved in Argentina, commercially launched in Spain, and awarded final pricing approval in Austria in Q4 2023 11
FY2024 ORLADEYO net revenue guidance initiated at $380-$400M; operating profit expected in 2024 without additional capital raise 10
R&D headcount reduced by 59 employees (10% of organization); late-stage out-licensing of BCX10013 planned to optimize capital allocation 10
“With nearly three years of launch data, we have excellent visibility into the pattern of growth for ORLADEYO and we remain on track to achieve the no less than $320 million in ORLADEYO revenues we have expected for 2023. Our solid base and the consistent addition of new patients each quarter, combined with the ongoing improvement in our percentage of paid patients and launches in new global markets, are all driving peak revenues to $1 billion.”
BCX10013 proof-of-concept trial first patient enrolled in October 2023; data from ongoing trial expected in 2024 9
License agreement entered with Clearside Biomedical to develop avoralstat for diabetic macular edema via SCS Microinjector; $5.0M upfront fee paid 9
ORLADEYO net revenue reached $85.7M in Q3 2023, +29.8% year-over-year, reaccelerating from Q2's 24.2% 8
“Our strong second quarter keeps us firmly on track to achieve no less than $320 million in ORLADEYO revenue this year, as our base of patients grows larger and larger every quarter. While ORLADEYO revenues continue to grow, we are also excited to host an R&D day in November to introduce new molecules and programs from our discovery platform that have the potential to replicate or exceed the success of ORLADEYO.”
BCX10013 dose-ranging trial sites opened for paroxysmal nocturnal hemoglobinuria patients; enrollment expected by year-end 2023 7
ORLADEYO net revenue reached $81.0M in Q2 2023, +24.2% year-over-year, down from 38% growth in Q1 2023 6
FY2023 ORLADEYO revenue guidance of no less than $320M confirmed; peak revenue trajectory of $1B reiterated 6
“The strong new patient growth in the first quarter, building on our large patient base with ORLADEYO, positions us very well to achieve our expectations for 2023, and advances us on a trajectory to peak sales of $1 billion. This growing revenue stream, alongside our robust balance sheet, has dramatically reduced our reliance on the capital markets as we drive value with continued commercial execution and disciplined investment in our pipeline.”
First patient enrolled in APeX-P pivotal trial evaluating ORLADEYO in pediatric HAE patients aged 2 to <12 years 5
Full-year 2023 ORLADEYO revenue guidance initiated at no less than $320M 4
BioCryst Pharmaceuticals Business Model
The BioCryst Pharmaceuticals business model in brief: products, customers and revenue sources as the company itself describes them in its reports. NadirAlpha methodology
BioCryst Pharmaceuticals is a commercial-stage biopharmaceutical company focused on rare diseases, with hereditary angioedema (HAE) as its primary therapeutic area. Its lead marketed product, ORLADEYO (berotralstat), is an oral once-daily plasma kallikrein inhibitor approved for HAE prevention in adults and adolescents, generating recurring prescription-based product revenue. Following the January 2026 acquisition of Astria Therapeutics, BioCryst added navenibart, an investigational injectable monoclonal antibody in Phase 3 development targeting HAE prevention with extended 3- and 6-month dosing intervals, which is being developed internally and licensed to regional partners. Revenue derives from ORLADEYO net product sales and partnership arrangements, including upfront and milestone payments from regional licensing deals such as those with Neopharmed Gentili for Europe and Torii for Japan. BioCryst Pharmaceuticals also advances earlier-stage pipeline candidates, including BCX17725, a KLK5 inhibitor in Phase 1 for Netherton syndrome. The June 2026 Board-approved closure of its Birmingham Discovery Center of Excellence marks a deliberate strategic shift away from internal early discovery toward concentrating resources on its HAE franchise and late-stage pipeline.
BioCryst Pharmaceuticals Stock: Share-Price Drivers
The drivers of BioCryst Pharmaceuticals stock from the company's perspective: demand, prices, costs and capacity as the investor relations reports describe them. NadirAlpha methodology
ORLADEYO generates the large majority of product revenue, led by the U.S. business, with additional European and rest-of-world contributions 30
U.S. ORLADEYO is the dominant revenue line and total quarterly revenue reached 218.2 million in 2026-Q2, with the growth flag marked accelerating 30 35
European and rest-of-world ORLADEYO revenue contribute alongside the U.S. business, and the pediatric oral pellet formulation launched in 2026 broadens the treated population 30 34 35
navenibart entered the Phase 3 program with ALPHA-ORBIT pivotal enrollment completed by 2026-06-30 and European rights licensed to Neopharmed Gentili; top-line results and regulatory filing are planned for later periods 35 34 33
BCX17725 is in early Phase 1 development with initial clinical data reads planned, an option to broaden the pipeline beyond HAE 30 33
2026-Q2 operating income was 98.5 million and operating cash flow 104.3 million, with the profitability flag positive and guidance raised 35
Sector trend: Demand for oral, at-home HAE prophylaxis continues to support uptake of ORLADEYO, and the company's operating margin has turned positive as revenue scales 35. Late-stage HAE competition and pipeline readouts (navenibart) shape the medium-term demand outlook 34.
BioCryst Pharmaceuticals Revenue by Type (as of 2026-Q2 · USD million · 5/5)
The segments of BioCryst Pharmaceuticals in the company's own definition, each row with its basis (3, 6 or 12 months), rows in grey are no longer reported separately. NadirAlpha methodology
| Segment | Since | Revenue | Source |
|---|---|---|---|
| Period FY2025 (12M) | |||
| ORLADEYO U.S. | FY2025 | 548.8 | 30 |
| License revenue | FY2025 | 244 | 30 |
| ORLADEYO European business | FY2025 | 38.7 | 30 |
| Other revenues | FY2025 | 29 | 30 |
| ORLADEYO Rest of world | FY2025 | 14.4 | 30 |
BioCryst Pharmaceuticals Products & announcements (53/118 active+recent)
What BioCryst Pharmaceuticals launched, had approved or announced, from the filings up to Q2 2026, each row with the date of first mention. NadirAlpha methodology
Status: PlannedLaunchedDiscontinued
| Product/Line | Since | Status | Source |
|---|---|---|---|
| 2027 | |||
| Navenibart US regulatory filing | 2027-12 | 33 | |
| Navenibart ALPHA-ORBIT top-line results both doses | 2027-09 | 35 | |
| Navenibart Phase 3 program (ALPHA-ORBIT and ORBIT-EXPANSE trials) | 2027 | 31 | |
| 2026 | |||
| BCX17725 clinical trial data for Netherton syndrome | 2026-12 | 30 | |
| BCX17725 Phase 1 trial data reporting for Part 4 | 2026-12 | 35 | |
| BCX17725 Part 4 Phase 1 trial data | 2026-12 | 33 | |
| ORLADEYO specialty pharmacy provider transition | 2026-08 | 34 | |
| ORLADEYO oral pellets launch in pediatric patients | 2026-08 | 35 | |
| ALPHA-ORBIT pivotal study enrollment completion | 2026-06 | 33 | |
| ALPHA-ORBIT enrollment completed | 2026-06 | 35 | |
| Birmingham facility closure (2×) | 2026-06 | (2026-12) | 35 |
| BCX17725 Phase 1 trial enrollment in healthy volunteers and Netherton syndrome patients | 2026-03 | 28 | |
| Blackstone term loan facility | 2026-01 | 34 | |
| BCX17725 Phase 1 trial for Netherton syndrome data readout | 2026 | 31 | |
| 2025 | |||
| ORLADEYO oral pellet formulation (7x) | 2025-12 | 32 | |
| ORLADEYO granules pediatric formulation (ages 2-11) | 2025-12 | 24 | |
| BCX17725 phase 1 initial data | 2025-12 | 24 | |
| Avoralstat phase 1 initial data | 2025-12 | 24 | |
| RAPIVAB/RAPIACTA/PERAMIFLU peramivir approved in United States, Canada, Australia, Japan, Taiwan, and Korea | 2025-09 | 28 | |
| Avoralstat Phase 1 trial enrollment announced in Australia | 2025-08 | 30 | |
| BCX17725 Fast Track designation (2x) | 2025-07 | 30 | |
| ORLADEYO approved by National Institute of Drug and Food Surveillance in Colombia | 2025-06 | 30 | |
| ORLADEYO Colombia approval (2x) | 2025-06 | 25 | |
| ORLADEYO pediatric granule formulation NDA | 2025-05 | 25 | |
| ORLADEYO pediatric granule formulation FDA priority review | 2025-05 | 25 | |
| BCX17725 investigational new drug application clearance | 2025-05 | 25 | |
| BCX17725 Phase 1 trial IND cleared by FDA | 2025-05 | 30 | |
| ASPR non-exercise of optional ordering periods under RAPIVAB contract | 2025-05 | 25 | |
| Pharmakon Loan prepayment ($50.0 million) (2x) | 2025-04 | 25 | |
| BCX17725 Phase 1 trial (Netherton syndrome) | 2025-03 | 27 | |
| ORLADEYO Portuguese Infarmed recommendation | 2025-02 | 21 | |
| navenibart Phase 3 enrollment | 2025 | 29 | |
| Oral C5 inhibitor clinical trials initiation | 2025 | 9 | |
| ORLADEYO reimbursement in Netherlands | 2025 | 20 | |
| ORLADEYO regulatory filings in Europe, Japan and Canada | 2025 | 23 | |
| ORLADEYO regulatory filing planned for pediatric indication (2x) | 2025 | 18 | |
| ORLADEYO pediatric granule formulation NDA filing to FDA | 2025 | 21 | |
| ORLADEYO oral granules for children with HAE aged 2-11 (4x) | 2025 | 22 | |
| ORLADEYO granules in children (aged 2 to <12) (2x) | 2025 | 27 | |
| Bifunctional complement inhibitor anti-C2 clinical trials initiation | 2025 | 9 | |
| BCX17725 phase 1 clinical trial enrollment | 2025 | 23 | |
| BCX17725 initial data expected | 2025 | 21 | |
| BCX17725 initial clinical data in Netherton syndrome | 2025 | 20 | |
| BCX17725 (Netherton syndrome) patient studies | 2025 | 19 | |
| Avoralstat initial clinical data targeted | 2025 | 21 | |
| Avoralstat clinical trial with suprachoroidal delivery (3x) | 2025 | 28 | |
| Avoralstat clinical trial advancement for DME (11x) | 2025 | 27 | |
| APeX-P pediatric trial | 2025 | 13 | |
| APeX-P pediatric ORLADEYO trial ongoing; supplemental NDA submission expected in 2025 | 2025 | 12 | |
| 2024 | |||
| Oral C2 inhibitor lead molecule selection (2x) | 2024 | 9 | |
| 2023 | |||
| APeX-P trial in pediatric HAE patients aged 2 to <12 years (6x) | 2023-01 | 25 | |
| 2021 | |||
| ORLADEYO supplemental NDA submission for pediatric use (3×) | 2021-02 | 12 | |
| 2020 | |||
| ORLADEYO FDA approval for prevention of HAE attacks in adults and pediatric patients ≥12 years (2×) | 2020-12 | 28 | |
| 2024 | |||
| BCX17725 clinical advancement | 2024-12 | 16 | |
| BCX17725 advancement into clinical trials for Netherton Syndrome | 2024-12 | 14 | |
| ORLADEYO Irish Health Services Executive recommendation | 2024-11 | 21 | |
| APeX-T observational study (2x) | 2024-11 | 17 | |
| BCX17725 Phase 1 trial enrollment started for Netherton syndrome | 2024-10 | 18 | |
| BCX17725 Phase 1 enrollment initiated for Netherton syndrome | 2024-10 | 21 | |
| BCX17725 (KLK5 inhibitor for Netherton syndrome) | 2024-09 | 17 | |
| Avoralstat (plasma kallikrein inhibitor for DME) | 2024-09 | 17 | |
| ASPR contract for RAPIVAB (95,625 doses over 5 years) (2x) | 2024-09 | 21 | |
| ORLADEYO approval in Peru | 2024-07 | 18 | |
| ORLADEYO Peruvian General Directorate of Medicines approval | 2024-07 | 21 | |
| ORLADEYO pediatric formulation (oral granule) for children as young as two years | 2024-06 | 15 | |
| ORLADEYO approval in Mexico | 2024-05 | 16 | |
| ORLADEYO Mexican Federal Commission approval for HAE prophylaxis | 2024-05 | 21 | |
| APeX-P trial enrollment completion for pediatric ORLADEYO oral granule formulation (ages 2-11) | 2024-05 | 21 | |
| APeX-P trial enrollment completed for pediatric ORLADEYO formulation | 2024-05 | 14 | |
| ORLADEYO approved in Brazil | 2024-04 | 16 | |
| ORLADEYO Brazilian Health Regulatory Agency approval | 2024-04 | 21 | |
| ORLADEYO final reimbursement in Italy | 2024-03 | 11 | |
| ORLADEYO reimbursement finalized in Italy | 2024-02 | 12 | |
| ORLADEYO approval in Italy | 2024-02 | 12 | |
| ORLADEYO Italian Medicines Agency reimbursement recommendation | 2024-02 | 21 | |
| Oral C5 inhibitor lead optimization completion | 2024 | 9 | |
| ORLADEYO pediatric formulation (APeX-P trial) | 2024 | 21 | |
| BCX17725 clinical trials initiation for Netherton syndrome | 2024 | 9 | |
| BCX17725 clinical trial initiation | 2024 | 21 | |
| BCX17725 clinical trial for Netherton syndrome | 2024 | 13 | |
| BCX17725 (KLK-5 inhibitor for Netherton syndrome) advancement into clinic | 2024 | 15 | |
| BCX10013 data reporting from proof-of-concept trial | 2024 | 9 | |
| 2023 | |||
| ORLADEYO pediatric trial ongoing | 2023-12 | 11 | |
| ORLADEYO final pricing approval in Austria | 2023-12 | 11 | |
| R&D Day at Discovery Center of Excellence in Birmingham, AL | 2023-11 | 8 | |
| R&D Day | 2023-11 | 6 | |
| ORLADEYO reimbursement approval in Austria | 2023-11 | 12 | |
| ORLADEYO marketing authorization in Spain | 2023-11 | 12 | |
| ORLADEYO launch in Spain | 2023-11 | 12 | |
| ORLADEYO approval in Austria | 2023-11 | 12 | |
| ORLADEYO approval in Argentina | 2023-11 | 12 | |
| BCX10013 proof-of-concept clinical trial patient enrollment (2x) | 2023-10 | 12 | |
| ORLADEYO - Japan | 2023-09 | 9 | |
| Austria ORLADEYO reimbursement approval | 2023-09 | 9 | |
| BCX10013 oral Factor D inhibitor in clinical development (3×) | 2023-09 | (2024-06) | 15 |
| BCX10013 dose-ranging trial enrollment (2x) | 2023-08 | 6 | |
| ORLADEYO approval in Chile | 2023-05 | 12 | |
| ORLADEYO marketing authorization in Chile | 2023-05 | 7 | |
| APeX-S Clinical Trial (ORLADEYO HAE) | 2023-04 | 7 | |
| ORLADEYO pediatric trial APeX-P | 2023-03 | 4 | |
| Canadian Drug Expert Committee positive recommendation for ORLADEYO | 2023-02 | 5 | |
| BCX10013 nonclinical study delay | 2023-02 | 5 | |
| APeX-P trial first patient enrollment | 2023-01 | 5 | |
| 2022 | |||
| ORLADEYO approval in Switzerland | 2022 | 12 | |
| ORLADEYO approval in Saudi Arabia | 2022 | 12 | |
| ORLADEYO approval in Israel | 2022 | 12 | |
| ORLADEYO approval in Canada | 2022 | 12 | |
| 2021 | |||
| ORLADEYO approval in United Kingdom | 2021 | 12 | |
| ORLADEYO approval in UAE | 2021 | 12 | |
| ORLADEYO approval in Japan | 2021 | 12 | |
| ORLADEYO approval in European Union | 2021 | 12 | |
| 2020 | |||
| ORLADEYO commercialization | 2020-12 | 21 | |
| ORLADEYO (berotralstat) | 2020-12 | 12 | |
| ORLADEYO | 2020-12 | 25 | |
| 2018 | |||
| Peramivir approval in Australia | 2018 | 12 | |
| 2017 | |||
| Peramivir approval in Canada | 2017 | 12 | |
| 2016 | |||
| Peramivir approval in Taiwan | 2016 | 12 | |
| 2014 | |||
| Peramivir approval in United States | 2014 | 12 | |
BioCryst Pharmaceuticals Transactions & Events (32)
32 transactions and events of BioCryst Pharmaceuticals from the original reports, financing measures and management changes are not listed here, cancelled items in grey. NadirAlpha methodology
Acquisitions by BioCryst Pharmaceuticals
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Navenibart exclusive commercialization rights to Neopharmed (Europe) | 2026-05 | Completed | 32 |
| Navenibart acquisition via Astria merger | 2026-01 | Completed | 30 |
| 2025 | |||
| Sale of European ORLADEYO business (7×) | 2025-10 | Completed | 27 |
| Astria Therapeutics acquisition | 2025-09 | Completed | 35 |
| Debt paydown of $75 million | 2025-04 | Completed | 22 |
| Annora ORLADEYO generic ANDA submission (6×) | 2025-01 | Completed | 30 |
| 2024 | |||
| ASPR RAPIVAB contract (5×) | 2024-09 | Completed | 30 |
| 2023 | |||
| Peramivir - Green Cross development/commercialization (2×) | 2023-09 | Completed | 18 |
| Galidesivir - BARDA/HHS contracts (expired 2022) | 2023-09 | Completed | 9 |
| Pharmakon debt facility (2×) | 2023-04 | Completed | 11 |
| BCX10013 development program (4×) | 2023-03 | Completed | 21 |
| BCX10013 out-licensing | 2023 | Completed | 10 |
Divestitures and exits by BioCryst Pharmaceuticals
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Avoralstat program termination | 2026-03 | Divested | 32 |
| Avoralstat development terminated | 2026-03 | Divested | 33 |
| 2025 | |||
| ASPR RAPIVAB base period completed; optional periods not exercised | 2025-05 | Divested | 28 |
| STAR-0310 strategic alternatives pursuit | 2025 | Divested | 30 |
| Avoralstat strategic partner search | 2025 | Divested | 30 |
| 2024 | |||
| Factor D programs discontinuation and close-out | 2024 | Divested | 21 |
| 2022 | |||
| BCX9930 Program Discontinuation (2x) | 2022-12 | Divested | 11 |
| BCX9250 Program Discontinuation | 2022-11 | Divested | 11 |
Partnerships and contracts of BioCryst Pharmaceuticals
| Transaction / stake | Date | Type | Source |
|---|---|---|---|
| 2026 | |||
| Navenibart licensing agreement with Neopharmed (3×) | 2026-05 | Agreement | 34 |
| 2025 | |||
| Navenibart Kaken License Agreement for Japan development and commercialization (2×) | 2025-08 | Agreement | 30 |
| 2024 | |||
| BCX10013 partnership or discontinuation decision (2×) | 2024-12 | Agreement | 13 |
| 2023 | |||
| Clearside Agreement for avoralstat with SCS Microinjector technology | 2023-11 | Agreement | 9 |
| Amended and Restated Commercialization and License Agreement with Torii (2×) | 2023-11 | Agreement | 21 |
| Torii Agreement - ORLADEYO commercialization Japan (2×) | 2023-09 | Agreement | 18 |
| Peramivir - Shionogi Agreement Japan/Taiwan | 2023-09 | Agreement | 9 |
| ORLADEYO Collaboration with Er-Kim Pharmaceuticals (Turkey) (3×) | 2023-07 | Agreement | 12 |
| ORLADEYO Collaboration with Pint Pharma (Pan-Latin America) | 2023-05 | Agreement | 7 |
| ORLADEYO commercialization agreement with Swixx BioPharma AG | 2023-01 | Agreement | 5 |
| Collaboration with Swixx BioPharma AG for ORLADEYO in Central and Eastern Europe | 2023-01 | Agreement | 12 |
| Clearside Biomedical avoralstat agreement (3x) | 2023 | Agreement | 12 |
BioCryst Pharmaceuticals Risks (187 since the annual report of 2026-02-26, 532 tracked in total)
Which risks BioCryst Pharmaceuticals has named since the annual report, company-specific first, generic standard risks in the expandable part; first mention refers to the document base from 2023. NadirAlpha methodology
Category: FinancialLegalCyberSupply chainRegulatoryStrategyTechnologyGeopoliticsMacroESGCustomersCompetitionPeopleMarket
| Risk | Category | Last reported |
|---|---|---|
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2026-08-05 (2026-Q2), source 35 | ||
| Results of BioCryst's partnerships with third parties may not meet expectations, partners may fail to reach milestones | = | |
| Uncertainties related to BioCryst's ability to successfully execute plan to close Birmingham facility and wind-down internal discovery | = | |
| BioCryst's ability to successfully transition to new sole source specialty pharmacy and commercialize ORLADEYO oral pellet | = | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2026-08-05 (2026-Q2), source 34 | ||
| Compromise of data security could result in violation of privacy laws, legal/regulatory/financial exposure, reputation damage, loss of confidence in security measures. | = | |
| May need additional capital or financing; insufficient funds could delay or eliminate development programs. | = | |
| May 6, 2026: manufacturing issue delayed ORLADEYO oral pellet fulfillment; resolved June 29, 2026. | = | |
| May 2026 manufacturing issue identified affecting ORLADEYO oral pellet formulation, resolved; new specialty pharmacy transition August 2026. | = | |
| Single-source reliance for certain manufacturing, distribution, and specialty pharmacy services. | = | |
| Annora filed Paragraph IV notices for ORLADEYO patents; lawsuit filed March 2025; four patents challenged (expiring May 2040). | = | |
| Partners may fail to perform, renegotiate, or terminate agreements; Torii partnership for ORLADEYO Japan carries execution risk. | = | |
| Acquisitions, partnerships, divestitures may divert management attention, dilute stockholder value, fail to meet expectations; Birmingham Closure Plan may increase acquisition reliance. | = | |
| Sale of European ORLADEYO business to Neopharmed may prevent maintaining global brand uniformity due to limited control over positioning and support. | = | |
| Merger benefits may not be realized; unknown risks from Astria business or navenibart product candidate. | = | |
| AI adoption presents risks around regulatory compliance, data protection, inadvertent confidential information release, vendor non-compliance with standards. | = | |
| Inflation, interest rates, banking instability may restrict future capital raising flexibility. | = | |
| Prior material weaknesses in internal control over financial reporting identified in 2023; remediated by December 2023 and September 2024. | = | |
| Geopolitical events may impact financing partners and suppliers; counterparty stability at risk. | = | |
| Multiple conflicting laws, export/import restrictions, and regulatory changes across jurisdictions. | = | |
| Natural disasters, pandemics, trade wars, armed conflicts, political unrest could disrupt operations and those of development partners, manufacturers, regulators. | = | |
| Reliance on third-party suppliers and CROs; failure to perform could delay development. | = | |
| Health epidemics or pandemics could disrupt operations, delay development/commercialization, increase costs, affect regulatory timelines, reduce capital access. | = | |
| Ineffective risk management, compliance, and audit systems could fail to identify and respond to business risks, materially adversely affecting operations. | = | |
| Anti-takeover provisions including staggered board terms, supermajority removal, preferred stock authority could delay or prevent acquisitions. | = | |
| Inflation Reduction Act, OBBBA, and Great Healthcare Plan Act impose pricing pressure and negotiation requirements. | = | |
| Product candidates may not receive FDA approval; regulatory delays or denials could prevent commercialization. | = | |
| Orphan drug designations may be changed or revoked; regulatory landscape for orphan drugs uncertain. | = | |
| Chevron doctrine overruling and FDA leadership changes create uncertainty in approval timelines. | = | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2026-05-06 (2026-Q1), source 32 | ||
| No assurance of sustained profitability; prior-year net loss due to acquired IPR&D charge for navenibart. | 2026-Q2 2026-08-05 34 | |
| Biosimilar products may compete with approved biologics after 12-year exclusivity window. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 10-K annual report of 2026-02-26 (FY2025), source 30 | ||
| Foreign currency exposure to Euro, Japanese Yen, Canadian Dollar impacts results. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2025-05-06 (2025-Q1), source 23 | ||
| Biotech sector stock prices highly volatile; company stock ranged $6.00 to $10.94 over 52 weeks; volatility unrelated to financial results. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 10-K annual report of 2025-02-25 (FY2024), source 21 | ||
| GDPR compliance fines up to 4% global revenue; evolving privacy laws require substantial resources. | 2026-Q2 2026-08-05 34 | |
| Clinical trials may fail to demonstrate efficacy or safety; enrollment or compliance challenges possible. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2025-01-10 (2024-Q4), source 19 | ||
| Statements regarding financial guidance may differ from actual results based on market factors and execution ability | 2026-Q2 2026-08-05 35 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2024-11-05 (2024-Q3), source 18 | ||
| Foreign CMO in China subject to BIOSECURE Act, sanctions, and trade restrictions. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2024-08-06 (2024-Q2), source 16 | ||
| Risk of inadvertent third-party patent infringement; patent position uncertain and highly litigious. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2024-05-07 (2024-Q1), source 14 | ||
| Top ten stockholders own approximately 50% of common stock and can influence significant corporate decisions and stockholder matters. | 2026-Q2 2026-08-05 34 | |
| Post-approval commitments, adverse event reporting, and manufacturing compliance requirements. | 2026-Q2 2026-08-05 34 | |
| Third-party payors challenge pricing; reimbursement changes affect demand and revenue. | 2026-Q2 2026-08-05 34 | |
| Hazardous materials use subject to federal, state, local environmental regulations. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2024-05-06 (2024-Q1), source 13 | ||
| BioCryst's ability to successfully progress pipeline development as described, including meeting expected timelines | 2026-Q2 2026-08-05 35 | |
| BioCryst Pharmaceuticals: first mention in 10-K annual report of 2024-02-27 (FY2023), source 12 | ||
| Annora filed ANDA with Paragraph IV notice in January 2025 and January 2026 for generic ORLADEYO; patent infringement lawsuit filed December 2025. | 2026-Q2 2026-08-05 34 | |
| Stockholder activism or hostile bids could divert management attention, create strategic uncertainty, impact business partner relationships, incur substantial legal costs. | 2026-Q2 2026-08-05 34 | |
| Unpredictable market and economic conditions including inflation, interest rates, FX fluctuations, geopolitical instability could adversely affect business and capital access. | 2026-Q2 2026-08-05 34 | |
| Generic approval of ORLADEYO could significantly reduce product sales post-exclusivity expiration. | 2026-Q2 2026-08-05 34 | |
| Increasing cyber threats including AI-based attacks; remote work and generative AI adoption heighten risks. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2024-01-08 (FY2023), source 10 | ||
| FDA may require additional studies beyond planned, may delay or withhold market approval for products and candidates | 2026-Q2 2026-08-05 35 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2023-11-08 (2023-Q3), source 9 | ||
| Facilities or vendor systems failure could result in loss of commercial product, clinical data. | 2026-Q2 2026-08-05 34 | |
| Small target patient populations for rare diseases may limit long-term revenue growth and sustainability. | 2026-Q2 2026-08-05 34 | |
| Extensive regulatory requirements; non-compliance could result in substantial penalties. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2023-11-02 (2023-Q3), source 8 | ||
| Ongoing and future preclinical and clinical development may take longer than expected and may not have positive results | 2026-Q2 2026-08-05 35 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2023-08-07 (2023-Q2), source 7 | ||
| Future issuances of common stock, options, RSUs could dilute current stockholders' ownership; 44.3M options/RSUs and 16M shares available under equity plans. | 2026-Q2 2026-08-05 34 | |
| Insurance increasingly costly and narrower in scope; potential uninsured losses could adversely affect operations and financial position. | 2026-Q2 2026-08-05 34 | |
| Inflation may increase operating expenses; potential adverse impact on results of operations. | 2026-Q2 2026-08-05 34 | |
| Risk of fraud, regulatory non-compliance, or confidential information misuse by employees. | 2026-Q2 2026-08-05 34 | |
| Trade secrets difficult to protect; non-compete restrictions increasing. | 2026-Q2 2026-08-05 34 | |
| Competitors with greater resources may achieve faster approvals and market dominance. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2023-08-03 (2023-Q2), source 6 | ||
| BioCryst may not be able to enroll required number of subjects in planned clinical trials | 2026-Q2 2026-08-05 35 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2023-05-08 (2023-Q1), source 5 | ||
| Blackstone Loan Agreement $400M term loan with prepayment premiums and restrictive covenants limiting operational flexibility. | 2026-Q2 2026-08-05 34 | |
| PhaRMA Notes $30M principal plus $20.6M accrued interest in default since 2014; foreclosure risk. | 2026-Q2 2026-08-05 34 | |
| Loss of senior management and key personnel could impede development objectives and commercial goals; intense competition for skilled personnel. | 2026-Q2 2026-08-05 34 | |
| Subject to ongoing disputes and potential securities litigation; unfavorable outcomes could harm reputation and divert management resources. | 2026-Q2 2026-08-05 34 | |
| Product liability insurance may be insufficient; claims could exceed coverage limits. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2023-05-03 (2023-Q1), source 4 | ||
| Approved products may fail to gain sufficient physician, patient, or payor acceptance. | 2026-Q2 2026-08-05 34 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2026-05-06 (2026-Q1), source 33 | ||
| Company recorded GAAP operating loss of $701.6 million in Q1 2026 due to acquired in-process R&D charge; accumulated deficit $2.228 billion | = | |
| Results from third-party partnerships may not meet expectations; partners may fail to reach performance milestones | = | |
| Ongoing and future clinical development of product candidates may take longer than expected with uncertain positive results | = | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2026-05-06 (2026-Q1), source 32 | ||
| $400M Blackstone Loan Agreement restricts asset sales, mergers, indebtedness, dividends. | = | |
| Blackstone Loan Agreement contains extensive covenants limiting asset disposals, mergers, indebtedness, dividend payments; covenant breach could trigger acceleration. | = | |
| Top ten stockholders own approximately 50% and influence corporate decisions | = | |
| Prepayment or mandatory repayment of Blackstone Loan before year 4 triggers premiums. | = | |
| Manufacturing issue disclosed May 6, 2026 affecting oral pellet formulation of ORLADEYO for pediatric patients; impact on future revenue uncertain. | = | |
| Peramivir revenues declined significantly after expiration of U.S. government ordering period; product commercialization uncertain. | = | |
| Foreign CMO in China subject to BIOSECURE Act, sanctions, trade restrictions. | = | |
| Biologic manufacturing highly susceptible to contamination, equipment failure, yield inconsistency. | = | |
| Specialty pharmacy, distributor, CRO performance failures could disrupt ORLADEYO commercialization. | = | |
| Annora ANDA Paragraph IV challenge filed 2025-2026; four patents expire 2039. | = | |
| Employees may wrongfully use third-party confidential information or trade secrets. | = | |
| Past and future disputes with partners could lead to costly litigation diverting management attention. | = | |
| Patent infringement litigation is expensive, time-consuming; adverse results risk patent validity. | = | |
| CCPA, GDPR violations could result in fines up to 4% global revenues or €20M. | = | |
| IRA, OBBBA, Great Healthcare Plan Act impose pricing limits, negotiate caps on drugs. | = | |
| Third-party payors increasingly challenging prices; formulary exclusion reduces usage. | = | |
| Partner termination or performance failure could reduce, delay or eliminate product revenues. | = | |
| Limited third-party manufacturers; single-source suppliers risk supply disruptions. | = | |
| AI and machine learning adoption increases cybersecurity risks and data breach exposure | = | |
| Company needs significant capital for clinical trials and commercialization; additional funding may not be available on acceptable terms. | = | |
| Unpredictable economic conditions and market instability affect capital access | = | |
| Small target populations for rare disease products; patient identification and access may be difficult; market may not develop as expected. | = | |
| Term loans subject to SOFR-based interest rate (effective 8.47% in Q1 2026); inflation could increase operating expenses. | = | |
| Hazardous materials use violations could result in substantial remediation costs. | = | |
| HHS galidesivir contract funding expired 2022; risks pending final closeout. | = | |
| Legal proceedings could harm reputation and divert management resources | = | |
| Supreme Court Chevron overturn may increase FDA legal challenges, disrupt operations. | = | |
| FDA staff reductions, reorganization could delay regulatory reviews and approvals. | = | |
| Reliance on third-party contractors, CROs, and manufacturing partners for development; failure to meet contractual obligations could delay programs. | = | |
| Preclinical and early clinical success does not guarantee later stage trial success; development plans may need modification based on regulatory feedback. | = | |
| Delayed regulatory approvals, manufacturing issues could impede commercial expectations. | = | |
| Ability to manage product pipeline and integrate acquisitions effectively; unknown risks associated with recently acquired Astria business. | = | |
| BioCryst Pharmaceuticals: first mention in 10-K annual report of 2026-02-26 (FY2025), source 30 | ||
| Blackstone Loan Agreement covenants restrict asset sales, acquisitions, dividends; prepayment penalties apply | = | |
| Continuing event of default on PhaRMA Notes; holders may foreclose on Royalty Sub collateral | = | |
| Third-party vendor disruptions and supply chain attacks threaten business continuity | = | |
| IRA drug price negotiation and limits on Medicare Part D pricing pressure revenues | = | |
| HHS did not exercise optional ordering periods under RAPIVAB contract after first period | = | |
| Ukraine-Russia and Middle East conflicts could lead to sanctions, embargoes and supply shortages | = | |
| Recession, market volatility, inflation, interest rate increases adversely affect capital access | = | |
| Global health concerns could prevent regulatory authorities from timely conducting inspections and reviews | = | |
| Natural disasters, pandemics, conflicts could disrupt operations and third-party supply chains | = | |
| FCPA prohibits improper payments to foreign officials; similar laws in UK/EU | = | |
| Subject to federal/state anti-kickback and false claims laws; foreign analogues apply | = | |
| EU Clinical Trials Regulation requires public disclosure; limited exemptions | = | |
| HIPAA; state laws (CCPA) stricter; civil/criminal penalties for violations | = | |
| Executive actions for 'most-favored-nation' pricing; states enacting price limits | = | |
| Track-and-trace requirements for prescription drugs at saleable unit level federally | = | |
| E-Privacy Directive replacement regulation timing uncertain; cookies/electronic marketing rules | = | |
| GDPR strict obligations on personal/health data; transfer restrictions; broad national variation | = | |
| Subject to import/export controls, tariffs, sanctions, trade barriers; foreign market limitations | = | |
| MHLW sets drug prices within 60-90 days; bi-annual price cuts; generics promotion | = | |
| UK Medical Devices Regulation divergence post-Brexit; GMP mutual recognition partial | = | |
| Competitors advancing faster via FDA programs or AI integration may gain market advantage | = | |
| Multiple HAE therapies in clinical development may compete with ORLADEYO and navenibart if approved | = | |
| Competitive influenza market with multiple approved products including seasonal vaccines and antivirals | = | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2026-01-12 (FY2025), source 29 | ||
| Significant indebtedness expected in connection with Astria merger; sufficient cash flow generation needed. | = | |
| Risks related to Astria merger close timing and potential termination of definitive agreement. | = | |
| Actual financial results may not be consistent with guidance ranges and timelines. | = | |
| Government decisions on pricing may not occur when expected or align with expectations. | = | |
| FDA may require additional studies, impose clinical holds, or delay/withhold market approvals. | = | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2025-11-04 (2025-Q3), source 28 | ||
| U.S. Government contracts subject to extraordinary provisions and compliance risks | = | |
| European ORLADEYO sale risks include margin sustainability, pipeline growth, milestone payment uncertainty | = | |
| Stockholder activism, proxy contests, hostile bids divert management attention and incur substantial costs | = | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2025-11-03 (2025-Q3), source 27 | ||
| Astria integration ongoing with risk of key employee loss, business disruption, and failure to realize anticipated synergies. | 2026-Q1 2026-05-06 32 | |
| BioCryst may not be able to enroll required number of subjects in planned clinical trials | 2026-Q1 2026-05-06 33 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2025-08-05 (2025-Q2), source 25 | ||
| Failure to meet milestones or payments could cause licensor termination. | 2026-Q1 2026-05-06 32 | |
| Disputes with employees, partners, vendors; potential securities class actions from stock price volatility | 2025-Q3 2025-11-04 28 | |
| U.S. Government contracts create increased risk of investigations, fraud allegations, and compliance penalties. | = | |
| Third parties challenging ORLADEYO patents; Annora filed ANDA in January 2025; litigation initiated March 2025. | = | |
| Clinical trials and commercialization expose company to product liability claims; insurance coverage may be insufficient. | = | |
| Delaware forum selection limits stockholder litigation options | = | |
| Employees from competitors may wrongfully use or disclose third-party confidential information; difficult to prevent. | = | |
| FDA or foreign regulatory delays/denials could prevent product commercialization and revenue generation. | = | |
| Failure of third-party development partners could delay or halt product candidate development. | = | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2025-08-04 (2025-Q2), source 24 | ||
| Anticipated sale of European ORLADEYO business still pending with execution risk on timing and conditions. | = | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2025-05-06 (2025-Q1), source 23 | ||
| Partnership disputes could result in litigation, substantial costs and management distraction. | = | |
| Staggered board, supermajority removal requirements, Delaware forum selection may delay acquisitions | 2025-Q3 2025-11-04 28 | |
| Exclusive Delaware forum provision may limit stockholder lawsuit options. | = | |
| Ineffective compliance and risk management systems could adversely affect business. | = | |
| BioCryst Pharmaceuticals: first mention in 10-K annual report of 2025-02-25 (FY2024), source 21 | ||
| Multiple conflicting regulations, political instability, wars, pandemics disrupt operations. | 2026-Q1 2026-05-06 32 | |
| Uncertainty around orphan drug exclusivity scope following Catalyst Pharms court decision and FDA clarification | FY2025 2026-02-26 30 | |
| Geopolitical instability, tariffs, trade restrictions, and government shutdowns disrupt operations | FY2025 2026-02-26 30 | |
| Competitive and technological advances could impact business success | FY2025 2026-02-26 30 | |
| Product candidates may be associated with adverse events or undesirable side effects requiring abandonment or limited development | 2025-Q3 2025-11-04 28 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2024-11-05 (2024-Q3), source 18 | ||
| Acquisitions and divestitures may fail to meet expectations or dilute value | 2026-Q1 2026-05-06 32 | |
| Ineffective risk management systems could adversely affect operations | 2026-Q1 2026-05-06 32 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2024-11-04 (2024-Q3), source 17 | ||
| Regulatory approval process complex and uncertain; failure to demonstrate safety/efficacy/benefit-risk could delay or prevent approval. | 2026-Q1 2026-05-06 32 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2024-08-06 (2024-Q2), source 16 | ||
| Cybersecurity incidents and data breaches risk IP loss, regulatory violations, operational disruption | FY2025 2026-02-26 30 | |
| Health epidemics or pandemics could materially disrupt business operations | 2026-Q1 2026-05-06 32 | |
| EU Artificial Intelligence Act and global AI governance emerging; disclosure/use implications | FY2025 2026-02-26 30 | |
| Patent positions uncertain; product candidates may not receive patent protection or patents may be challenged | FY2025 2026-02-26 30 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2024-08-05 (2024-Q2), source 15 | ||
| Results of third-party partnerships may not meet current expectations. | FY2025 2026-01-12 29 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2024-05-07 (2024-Q1), source 14 | ||
| Physical damage or power loss at facilities could destroy products, samples, data. | 2026-Q1 2026-05-06 32 | |
| Inflation Reduction Act: mandatory Medicare price-setting from 2026; rebates on price increases | FY2025 2026-02-26 30 | |
| Physician Sunshine Act transparency; state laws require pricing/marketing disclosure | FY2025 2026-02-26 30 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2024-05-06 (2024-Q1), source 13 | ||
| Commercial viability of ORLADEYO and achievement of sustained market acceptance uncertain. | FY2025 2026-01-12 29 | |
| Timing for achieving or sustainability of profitability and positive cash flow uncertain. | FY2025 2026-01-12 29 | |
| No assurance commercialization methods and strategies will succeed or market will develop as expected | FY2025 2026-02-26 30 | |
| BioCryst Pharmaceuticals: first mention in 10-K annual report of 2024-02-27 (FY2023), source 12 | ||
| PhaRMA Notes in default since 2014; Royalty Sub unable to pay full interest due on Shionogi royalty financing | FY2025 2026-02-26 30 | |
| EUR, GBP, JPY, CAD fluctuations impact revenues and expenses. | 2026-Q1 2026-05-06 32 | |
| Third-party payors challenging prices; cost-containment measures impact revenues | FY2025 2026-02-26 30 | |
| Future ORLADEYO revenue depends on multiple factors including patient demand, reimbursement and pricing strategy | FY2025 2026-02-26 30 | |
| Failure to comply with cGMP regulations may result in civil and criminal liability | FY2025 2026-02-26 30 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2023-11-08 (2023-Q3), source 9 | ||
| Failed post-approval studies or commitments could delay or prevent continued approval. | 2026-Q1 2026-05-06 32 | |
| AI tool integration without disclosure risks confidential data exposure and regulatory non-compliance | FY2025 2026-02-26 30 | |
| GDPR and CCPA compliance failures risk fines up to 4% revenue; operational disruption | FY2025 2026-02-26 30 | |
| Potential future securities class action lawsuits if stock price becomes volatile | FY2025 2026-02-26 30 | |
| third-party patent claims may delay development or force costly licenses | 2025-Q3 2025-11-04 28 | |
| Material weaknesses in internal control over financial reporting could impair accuracy | 2026-Q1 2026-05-06 32 | |
| Regulatory authorities have broad discretion in granting orphan drug designations; changes to regulations could impact business. | 2026-Q1 2026-05-06 32 | |
| Competitors have greater resources, experience; may achieve faster regulatory approvals. | 2026-Q1 2026-05-06 32 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2023-08-07 (2023-Q2), source 7 | ||
| GDPR-related fines, bans on data processing, litigation could harm business. | 2026-Q1 2026-05-06 32 | |
| BioCryst may face regulatory delays or restrictive approvals from FDA or other agencies on product candidates | 2026-Q1 2026-05-06 33 | |
| May need additional capital to complete development and commercialization of product candidates | FY2025 2026-02-26 30 | |
| Efficiency of manufacturing processes by third parties could affect operations | FY2025 2026-02-26 30 | |
| Loss of key scientists and management impedes development and commercialization objectives | FY2025 2026-02-26 30 | |
| BioCryst Pharmaceuticals: first mention in 10-Q quarterly report of 2023-05-08 (2023-Q1), source 5 | ||
| Healthcare fraud and abuse law violations risk fines, debarment from Medicare/Medicaid programs | FY2025 2026-02-26 30 | |
| Natural disasters and geopolitical conflicts disrupt operations and supply chains | 2026-Q1 2026-05-06 32 | |
| Computer system failure could cause data loss, inaccurate calculations. | 2026-Q1 2026-05-06 32 | |
| BioCryst Pharmaceuticals: first mention in 8-K-EX99.1 earnings release of 2023-05-03 (2023-Q1), source 4 | ||
| FDA or other regulatory agencies may impose clinical holds or delay or withhold market approvals for products | 2026-Q1 2026-05-06 33 | |
BioCryst Pharmaceuticals Reported KPIs (as disclosed) (242)
NadirAlpha collects 242 reported KPIs of BioCryst Pharmaceuticals from the filings up to Q2 2026; the definition comes from the company, period and source are stated at every value. NadirAlpha methodology
| KPI | Value / change | Source |
|---|---|---|
| BioCryst Pharmaceuticals, published 2026-08-05, period 2026-Q2 | ||
| Cash and equivalents and investments | $352.6 million | 34 |
| Total revenue growth (y-o-y) | +34% | 35 |
| Total revenue growth (y-o-y comparable basis excluding European revenue) | +45% | 35 |
| ORLADEYO revenue growth (y-o-y) | +1% | 35 |
| ORLADEYO revenue growth (y-o-y comparable basis excluding European revenue) | +10% | 35 |
| ORLADEYO global peak market | $1 billion | 34 |
| Neopharmed upfront consideration | $70.0 million | 34 |
| Neopharmed royalties | 18% to 30% | 34 |
| Neopharmed regulatory and sales milestones | up to $275.0 million | 34 |
| Cash and cash equivalents and investments | $354.0 million | 35 |
| Blackstone Term Loans | $400.0 million | 34 |
| BioCryst Pharmaceuticals, published 2026-05-06, period 2026-Q1 | ||
| Withholding taxes paid on stock-based awards | $1.2 million | 32 |
| Total revenues | $156.4 million | 32 |
| Total revenues | $145.5 million | 32 |
| Total cost of product sales | $5.4 million | 32 |
| Total cost of product sales | $4.6 million | 32 |
| Total SG&A | $94.6 million | 32 |
| Total SG&A | $82.5 million | 32 |
| Total R&D | $60.3 million | 32 |
| Total R&D | $37.3 million | 32 |
| Total ORLADEYO | $148.3 million | 32 |
| Total ORLADEYO | $134.2 million | 32 |
| Stock-based compensation SG&A | $9.2 million | 32 |
| Stock-based compensation SG&A | $12.8 million | 32 |
| Stock-based compensation R&D | $6.8 million | 32 |
| Stock-based compensation R&D | $8.5 million | 32 |
| Sales and maturities of investment securities | $221.2 million | 32 |
| Sales and marketing | $43.0 million | 32 |
| Sales and marketing | $38.5 million | 32 |
| STAR 0310 R&D | $0.7 million | 32 |
| STAR 0310 R&D | $0 million | 32 |
| Research discovery and preclinical programs | $4.0 million | 32 |
| Research discovery and preclinical programs | $3.0 million | 32 |
| Purchases of investment securities | $48.8 million | 32 |
| Pro-forma cash position | 330.8 million | 33 |
| Post close transition services income | $1.2 million | 32 |
| Other revenues | $5.0 million | 32 |
| Other revenues | $11.3 million | 32 |
| Other non program specific and indirect costs | $7.4 million | 32 |
| Other non program specific and indirect costs | $6.5 million | 32 |
| Other expense net | $1.5 million | 32 |
| ORLADEYO revenue Q1 2026 y-o-y growth comparable basis | +21% | 33 |
| ORLADEYO revenue Q1 2026 y-o-y growth | +11% | 33 |
| ORLADEYO revenue | $148.3 million | 32 |
| ORLADEYO revenue | 148.3 million | 33 |
| ORLADEYO revenue | $122.7 million | 32 |
| ORLADEYO global peak market potential | $1 billion | 32 |
| Net proceeds from Term Loans | $395.0 million | 32 |
| Net increase in cash | $82.0 million | 32 |
| Net increase in cash | $0.6 million | 32 |
| Net foreign currency losses | $0.2 million | 32 |
| Net foreign currency gains | less than $0.1 million | 32 |
| Net cash used in operating activities | $(61.8) million | 32 |
| Net cash used in operating activities | $(27.5) million | 32 |
| Net cash used in investing activities | $(268.6) million | 32 |
| Net cash provided by investing activities | $27.1 million | 32 |
| Net cash provided by financing activities | $412.6 million | 32 |
| Net cash provided by financing activities | $0.5 million | 32 |
| Neopharmed navenibart upfront consideration | $70.0 million | 32 |
| Neopharmed navenibart tiered royalties | 18% to 30% | 32 |
| Neopharmed navenibart regulatory and sales milestone payments | up to $275.0 million | 32 |
| Navenibart R&D | $9.7 million | 32 |
| Navenibart R&D | $0 million | 32 |
| Maturities of investment securities | $76.0 million | 32 |
| Mark to market adjustment | $2.8 million | 32 |
| License revenue | $3.0 million | 32 |
| License revenue | $0 million | 32 |
| Interest income | $2.3 million | 32 |
| Interest income | $3.0 million | 32 |
| Interest expense | $19.8 million | 32 |
| Interest expense | $23.5 million | 32 |
| Income tax expense | $1.0 million | 32 |
| Income tax expense | $0.7 million | 32 |
| General and administrative | $42.4 million | 32 |
| General and administrative | $19.5 million | 32 |
| European ORLADEYO business SG&A | $11.6 million | 32 |
| European ORLADEYO business R&D | $0.2 million | 32 |
| European ORLADEYO business | $11.5 million | 32 |
| European ORLADEYO business COGS | $0.7 million | 32 |
| Effect of exchange rates | $(0.1) million | 32 |
| Effect of exchange rates | $0.5 million | 32 |
| Cost of product sales peramivir | $2.7 million | 32 |
| Cost of product sales peramivir | $2.6 million | 32 |
| Cost of product sales ORLADEYO | $2.7 million | 32 |
| Cost of product sales ORLADEYO | $1.3 million | 32 |
| Compensation and related personnel costs R&D | $27.1 million | 32 |
| Compensation and related personnel costs R&D | $12.2 million | 32 |
| Common stock issued under stock based compensation plans | $19.5 million | 32 |
| Cash, cash equivalents, restricted cash and investments | 260.8 million | 33 |
| Cash paid for acquisition Astria | $489.5 million | 32 |
| Cash and cash equivalents March 31 | $259.0 million | 32 |
| Blackstone interest rate effective | 8.47% | 32 |
| Blackstone additional term loans available | up to $150.0 million | 32 |
| Blackstone Term Loans principal | $400.0 million | 32 |
| Blackstone Loan maturity date | January 23, 2031 | 32 |
| Berotralstat R&D | $1.8 million | 32 |
| Berotralstat R&D | $1.9 million | 32 |
| BCX17725 R&D | $1.9 million | 32 |
| BCX17725 R&D | $2.5 million | 32 |
| Avoralstat R&D | $0.9 million | 32 |
| Avoralstat R&D | $2.5 million | 32 |
| Astria merger exchange ratio | 0.59 shares | 32 |
| Astria merger cash consideration | $8.55 per share | 32 |
| Acquired in-process R&D expense | $697.8 million | 32 |
| BioCryst Pharmaceuticals, published 2026-02-26, period FY2025 | ||
| Cash and equivalents | 335.9 million | 30 |
| ORLADEYO global peak market potential | $1 billion in annual net ORLADEYO revenues | 30 |
| BioCryst Pharmaceuticals, published 2026-02-26, period 2025-Q4 | ||
| Stockholders' deficit | $(119,153) | 31 |
| Royalty financing obligation | $465,688 | 31 |
| Restricted cash | $1,601 | 31 |
| Cash, cash equivalents and investments | $335,911 | 31 |
| Accumulated deficit | $(1,506,179) | 31 |
| BioCryst Pharmaceuticals, published 2025-11-04, period 2025-Q3 | ||
| ORLADEYO | $159.4 million | 28 |
| ORLADEYO peak market potential | $1 billion in annual net ORLADEYO revenues | 28 |
| ORLADEYO | $468.3 million | 28 |
| BioCryst Pharmaceuticals, published 2025-11-03, period 2025-Q3 | ||
| U.S. contribution to global ORLADEYO net revenues Q3 | 89 percent | 27 |
| Pro forma cash balance | 294 million | 27 |
| ORLADEYO net revenue | 159.1 million | 27 |
| ORLADEYO net revenue | 116.3 million | 27 |
| New ORLADEYO prescribers in U.S. Q3 | 64 | 27 |
| Cash, cash equivalents and investments | 269.4 million | 27 |
| BioCryst Pharmaceuticals, published 2025-08-05, period 2025-Q2 | ||
| ORLADEYO peak revenue potential | $1 billion in annual net revenues | 25 |
| Net income | 5.1 million | 25 |
| Cash and cash equivalents | 285.2 million | 25 |
| BioCryst Pharmaceuticals, published 2025-08-04, period 2025-Q2 | ||
| U.S. share of global ORLADEYO revenue Q2 | 89.5 percent | 24 |
| ORLADEYO net revenue | $156.8 million | 24 |
| ORLADEYO net revenue | $108.3 million | 24 |
| New prescribers | 69 | 24 |
| BioCryst Pharmaceuticals, published 2025-05-06, period 2025-Q1 | ||
| Expected U.S. revenue at peak | approximately 80 percent | 23 |
| Cash and equivalents | $105.2 million | 23 |
| Available-for-sale investments | $210.5 million | 23 |
| Pharmakon Loan prepayment | $75.0 million | 23 |
| Pharmakon Loan outstanding principal before prepayment | $300.0 million | 23 |
| ORLADEYO revenue peak | $1 billion in annual net ORLADEYO revenues | 23 |
| BioCryst Pharmaceuticals, published 2025-05-05, period 2025-Q1 | ||
| U.S. contribution to ORLADEYO revenue | 89.5 percent | 22 |
| Paid ORLADEYO patients share | approximately 84 percent | 22 |
| ORLADEYO revenue growth YoY | +51 percent | 22 |
| ORLADEYO revenue | 134.2 million | 22 |
| Net cash utilization | 25.5 million | 22 |
| Interest savings over life of loan | approximately 23.5 million | 22 |
| HAE patients preferring oral prophylaxis | 70 percent | 22 |
| Debt paydown | 75 million | 22 |
| Cash, cash equivalents, restricted cash & investments | 317.3 million | 22 |
| BioCryst Pharmaceuticals, published 2025-02-25, period FY2024 | ||
| Cash and cash equivalents | approximately $104.7 million | 21 |
| Available-for-sale investments | approximately $236.5 million | 21 |
| ORLADEYO peak revenue potential | $1 billion | 21 |
| ORLADEYO U.S. revenue pct at peak | 80 percent | 21 |
| BioCryst Pharmaceuticals, published 2025-02-24, period 2024-Q4 | ||
| U.S. patients on paid product | 73.5% | 20 |
| Stockholders' deficit | (475,934) | 20 |
| Operating cash use | $8.4 million | 20 |
| ORLADEYO net revenue | $124.2 million | 20 |
| ORLADEYO net revenue | $437.7 million | 20 |
| International sales percentage | 13.9% | 20 |
| International sales percentage | 11.8% | 20 |
| HAE treaters considering ORLADEYO | 97% | 20 |
| Current prescribers extremely likely to prescribe more | 59% | 20 |
| Cash, cash equivalents, restricted cash and investments | $342.8 million | 20 |
| Accumulated deficit | (1,770,040) | 20 |
| BioCryst Pharmaceuticals, published 2025-01-10, period 2024-Q4 | ||
| Total revenue y-o-y growth | +40 percent | 19 |
| Total revenue y-o-y growth | +36 percent | 19 |
| Physicians prescribed ORLADEYO | Over 1,200 | 19 |
| ORLADEYO y-o-y growth | +36 percent | 19 |
| ORLADEYO annual growth | 34 percent | 19 |
| ORLADEYO annual growth | 30 percent | 19 |
| Countries with patient access | Over 30 | 19 |
| BioCryst Pharmaceuticals, published 2024-11-05, period 2024-Q3 | ||
| Investments available for sale | 252.6 | 18 |
| Cash and cash equivalents | 96.8 | 18 |
| BioCryst Pharmaceuticals, published 2024-11-04, period 2024-Q3 | ||
| Start forms growth | 14.2% | 17 |
| Reimbursed product rate US | 74.8% | 17 |
| Patient switch rate | approximately 50% | 17 |
| Operating cash increase Q3 | 13.1 million | 17 |
| ORLADEYO revenue growth YoY | 35.7% | 17 |
| ORLADEYO net revenue | $116.3 million | 17 |
| New prescribers Q3 | 67 | 17 |
| International revenue contribution | 11.4% | 17 |
| GAAP operating profit Q3 | 7.7 million | 17 |
| Cash, cash equivalents & investments | 351.7 million | 17 |
| BioCryst Pharmaceuticals, published 2024-08-06, period 2024-Q2 | ||
| Pharmakon loan tranche A | 300.0 | 16 |
| Non-cash interest expense | 28.5 | 16 |
| Non-cash interest expense | 14.3 | 16 |
| Investments available for sale | 257.9 | 16 |
| Interest expense Pharmakon | 20.6 | 16 |
| Interest expense Pharmakon | 10.4 | 16 |
| Effective interest rate | 13.31% | 16 |
| Cash and cash equivalents | 78.4 | 16 |
| BioCryst Pharmaceuticals, published 2024-08-05, period 2024-Q2 | ||
| Operating cash use | 0.2 million | 15 |
| Cash, cash equivalents, restricted cash & investments | 338.1 million | 15 |
| Allergist/immunologist prescription likelihood | 52 percent | 15 |
| ORLADEYO patient retention | more than 60 percent | 15 |
| ORLADEYO paid patient rate | 74.4 percent | 15 |
| ORLADEYO international countries | more than 20 countries | 15 |
| ORLADEYO ex-US revenue percentage | 11 percent | 15 |
| BioCryst Pharmaceuticals, published 2024-05-06, period 2024-Q1 | ||
| Net cash utilization | 52.4 | 13 |
| Cash, cash equivalents, restricted cash and investments | 338.4 | 13 |
| BioCryst Pharmaceuticals, published 2024-02-27, period FY2023 | ||
| Total revenues | $331.4 million | 12 |
| Selling, general & administrative expenses | $213.9 million | 12 |
| Research & development expenses | $216.6 million | 12 |
| Pharmakon Loan outstanding principal | $313.7 million | 12 |
| Net working capital | $346.0 million | 12 |
| Interest expense | $108.2 million | 12 |
| Cost of product sales | $4.5 million | 12 |
| Cash and equivalents | $110.6 million | 12 |
| Available-for-sale investments | $278.3 million | 12 |
| Pharmakon Loan Tranche A interest rate | 13.30% | 12 |
| Pharmakon Loan Tranche A borrowing amount | $300.0 million | 12 |
| ORLADEYO revenue | $326.0 million | 12 |
| BioCryst Pharmaceuticals, published 2024-02-26, period 2023-Q4 | ||
| U.S. patients on paid or long-term free product | 1,104 | 11 |
| Percentage of U.S. patients on paid product | 71.5 percent | 11 |
| Net U.S. patient growth in | 321 | 11 |
| 2024 SG&A expenses expected increase | 20 million | 11 |
| 2024 R&D expenses expected reduction versus | 20-30 million | 11 |
| 2024 Full year operating expenses expected | 365-375 million | 11 |
| BioCryst Pharmaceuticals, published 2024-01-08, period FY2023 | ||
| SG&A expense increase 2024 vs. | $20 million | 10 |
| R&D expense reduction 2024 vs. | $20 million | 10 |
| ORLADEYO Q4 2023 year-over-year growth | +27 percent | 10 |
| ORLADEYO 2023 year-over-year growth | +29 percent | 10 |
| Jobs reduction | 59 jobs (10 percent of total organization) | 10 |
| BioCryst Pharmaceuticals, published 2023-11-08, period 2023-Q3 | ||
| Net working capital | $411.7 million | 9 |
| Investments available for sale | $246.7 million | 9 |
| Cash and cash equivalents | $150.9 million | 9 |
| ORLADEYO global peak revenue potential | $1 billion in annual net ORLADEYO revenues | 9 |
| ORLADEYO US revenue at peak percentage | at least 70 to 80 percent | 9 |
| BioCryst Pharmaceuticals, published 2023-11-02, period 2023-Q3 | ||
| Sales from outside the U.S. (percentage of global ORLADEYO net revenues) | 12.2 percent | 8 |
| Operating cash use | 16.5 million | 8 |
| BioCryst Pharmaceuticals, published 2023-08-07, period 2023-Q2 | ||
| Net working capital | $417.6 million | 7 |
| Investments available for sale | $264.5 million | 7 |
| Cash and equivalents | $146.2 million | 7 |
| ORLADEYO US revenue at peak pct | 70 to 80 percent | 7 |
| ORLADEYO global peak revenue | $1 billion | 7 |
| BioCryst Pharmaceuticals, published 2023-08-03, period 2023-Q2 | ||
| Operating cash use | $13.5 million | 6 |
| ORLADEYO international revenue pct | 10.1 percent | 6 |
| ORLADEYO Q2 2023 revenue | $81.0 million | 6 |
| ORLADEYO Q2 2023 growth yoy | +24.2 percent | 6 |
| Cash equivalents investments June 30 | $414,115 | 6 |
| BioCryst Pharmaceuticals, published 2023-05-08, period 2023-Q1 | ||
| Global peak ORLADEYO revenue | $1 billion in annual net ORLADEYO revenues | 5 |
| ORLADEYO peak revenue from United States | at least 70 to 80 percent | 5 |
| BioCryst Pharmaceuticals, published 2023-05-03, period 2023-Q1 | ||
| U.S. patients on therapy y-o-y growth | 46 percent | 4 |
| U.S. patients on therapy q-o-q growth | eight percent | 4 |
| U.S. patients on ORLADEYO therapy | over 1,000 | 4 |
| U.S. patient start forms growth | 20 percent | 4 |
| Pro forma cash post-debt refinancing | approximately 429 million | 4 |
| Operating cash use | 40.8 million | 4 |
| International sales contribution to ORLADEYO revenue | 11.1 percent | 4 |
BioCryst Pharmaceuticals Development
A condensed summary of BioCryst Pharmaceuticals per reporting period as running text: what changed operationally, which drivers management names, how earnings and cash flow developed. NadirAlpha methodology
FY2026: BioCryst Pharmaceuticals
BioCryst completed the acquisition of Astria Therapeutics on January 23, 2026, adding navenibart, a Phase 3 monoclonal antibody in development for hereditary angioedema prevention, and STAR-0310 to its pipeline; the transaction triggered a non-cash acquired in-process research and development charge of $697.8 million that produced a first-quarter operating loss of 701.6 million and a net loss of 721.8 million 32 33. To finance the acquisition, BioCryst entered into a $400.0 million term loan with Blackstone on January 23, 2026, maturing January 23, 2031 32. Second-quarter total revenues reached 218.2 million, including $55.7 million recognized from the navenibart licensing agreement with Neopharmed Gentili and ORLADEYO net revenue of $158.2 million, with operating income at 98.5 million 34 35. BioCryst raised its full year 2026 total revenue guidance to $690 million to $715 million and announced the discontinuation of internal discovery programs along with the closure of its Birmingham Discovery Center of Excellence by end of 2026 35 34.
FY2025: BioCryst Pharmaceuticals
BioCryst Pharmaceuticals reported total revenues of $874.8 million for FY2025, up from $450.7 million in 2024, with the increase driven primarily by $243.3 million in one-time license revenue from the divestiture of its European ORLADEYO business to Neopharmed Gentili and ORLADEYO product revenue growth of 38% year-over-year to $601.8 million (30, 31). BioCryst Pharmaceuticals recorded FY2025 GAAP operating income of $341.0 million and net income of $263.9 million, achieving full-year profitability for the first time in company history, with non-GAAP operating income of $214.2 million reflecting underlying operational performance (31). ORLADEYO net revenue growth was supported throughout the year by rising paid prescription rates, increased prescriber adoption, and expanding patient preference for oral HAE prophylaxis, with the U.S. prescriber base showing 97% considering ORLADEYO prescriptions by year-end (22, 27). Completion of the European business divestiture in October 2025 enabled full retirement of the Pharmakon term loan, with BioCryst ending 2025 in a net cash position of $89.7 million after paying down $323.7 million in total Pharmakon debt during the year (31). FDA approval of ORLADEYO oral pellets for pediatric patients aged 2 to under 12 years in December 2025 and the signed merger agreement with Astria Therapeutics, bringing navenibart into the HAE portfolio, represented the principal portfolio expansions during the period (31).
FY2024: BioCryst Pharmaceuticals
BioCryst Pharmaceuticals generated total revenue of $450.7 million in FY2024, up approximately 36% year-over-year, with ORLADEYO net revenue of $437.7 million representing 34% growth driven by volume gains and price increases 31 21. The GAAP operating loss narrowed sharply to $2.5 million from $103.7 million in 2023, while non-GAAP operating income reached $71.9 million, supported by a $42 million year-over-year reduction in R&D expenses following the discontinuation of the Factor D inhibitor programs 31 20 21. Net loss for the full year was $88.9 million ($0.43 per diluted share), and net cash used in operating activities totaled $52.0 million; year-end liquidity comprised $104.7 million in cash equivalents and $236.5 million in available-for-sale investments 31 21. During 2024, BCX10013 was discontinued after clinical evaluation showed insufficient activity versus market alternatives, BCX17725 entered Phase 1 trials for Netherton syndrome, and the U.S. Department of Health and Human Services awarded a contract of up to $69 million for RAPIVAB procurement 21 18. ORLADEYO received regulatory approvals in Italy, Brazil, Mexico, and Peru and was commercially available in more than 30 countries by year-end, with the paid patient rate in the U.S. rising to 73.5% 21 20.
FY2023: BioCryst Pharmaceuticals
BioCryst Pharmaceuticals reported FY2023 total revenues of $331.4 million, up from $270.8 million in 2022, driven by ORLADEYO (berotralstat) net revenue of $326.0 million, representing approximately 29% year-over-year growth 12. BioCryst Pharmaceuticals recorded an operating loss of $103.7 million and a net loss of $226.5 million for the year, as SG&A expenses increased 34% to $213.9 million to support commercial expansion while R&D expenses declined 14% to $216.6 million following the discontinuation of the BCX9930 and BCX9250 programs 11. In April 2023, BioCryst refinanced its debt through a new $300 million Pharmakon Tranche A loan, replacing the prior Athyrium credit facility and recording a $29.0 million loss on debt extinguishment 7. The U.S. patient base on paid or long-term free ORLADEYO reached 1,104 at year-end, up 30% year-over-year, while international market access expanded through new regulatory approvals and commercial collaborations in Argentina, Spain, Austria, Chile, and Turkey 11. In January 2024, the company announced a 10% R&D workforce reduction, a plan to out-license BCX10013, and projected operating profit for full-year 2024 10.
Glossary
- Revenue: Revenue from contracts with customers, net of sales deductions, as the company itself reports it; not total output, gross revenue, GMV or order intake.
- Op. income: The operating line of the income statement; EBIT only as a marked fallback, never pre-tax or ordinary income.
- Op. income (adj.): Adjusted operating income, verbatim and company-defined (non-GAAP), never derived.
- Net income: Net income attributable to the shareholders of the parent, after discontinued operations; not the result including minority interests, not comprehensive income.
- EPS: Diluted earnings per share attributable to the shareholders of the parent; a printed figure always beats a calculated one, calculated values are marked.
- FCF: Free cash flow = operating cash flow minus capital expenditure on property, plant and equipment; the company's own free cash flow figure is shown separately.
- OCF: Cash flow from operating activities as reported; IFRS companies may show interest paid in financing cash flow, so the figure is not always comparable.
- Cash: Cash and cash equivalents, without securities unless the company reports them as part of the position.
- Net Debt: Net debt = financial debt excluding lease liabilities minus cash at the same reporting date; the company's own net position may differ.
- *: derived, the formula is in the hover
- ≈: calculated, approximation
- ~: uncertain; the value stays visible, verdicts do not use it
- °: repaired by a targeted query against the document, or curated with documentary evidence
- EBIT: EBIT as a fallback: the income statement carries no operating line
- basic: basic earnings per share as a fallback when diluted is missing
Sources: quarterly reports, annual reports and investor relations documents
The evidence base for BioCryst Pharmaceuticals stock: every document with type and date, every figure in the report leads here by number and to the original by link. NadirAlpha methodology
Older sources (+17)
| # | Document type | Published |
|---|---|---|
| #201 | 10-Q quarterly report | 2016-05-09 |
| #202 | 10-Q quarterly report | 2016-08-08 |
| #203 | 10-Q quarterly report | 2016-11-08 |
| #204 | 10-K annual report | 2017-02-27 |
| #206 | 10-K annual report | 2017-02-27 |
| #205 | 10-Q quarterly report | 2017-08-08 |
| #208 | 10-K annual report | 2018-03-12 |
| #207 | 10-Q quarterly report | 2018-08-09 |
| #210 | 10-K annual report | 2019-03-14 |
| #209 | 10-Q quarterly report | 2019-08-08 |
| #214 | 10-K annual report | 2020-03-13 |
| #211 | 10-Q quarterly report | 2020-05-11 |
| #212 | 10-Q quarterly report | 2020-08-07 |
| #213 | 10-Q quarterly report | 2020-11-06 |
| #215 | 10-Q quarterly report | 2021-05-07 |
| #216 | 10-Q quarterly report | 2021-08-09 |
| #217 | 10-Q quarterly report | 2021-11-04 |
BioCryst Pharmaceuticals Stock FAQ
Is there a management forecast (guidance) for FY2026?
Yes. Management has issued targets for FY2026, including Revenue. The guidance tracking chapter shows all targets and checks them against the actuals reported later; neutral, with no estimate of our own.
Which additional key figures does BioCryst Pharmaceuticals report?
As reported for Q2 2026: Total revenue growth (y-o-y), ORLADEYO revenue growth (y-o-y), ORLADEYO global peak market, Neopharmed upfront consideration, Neopharmed royalties, Neopharmed regulatory and sales milestones. The chapter Reported KPIs lists every value with its source. Revenue is broken down by ORLADEYO U.S., License revenue, ORLADEYO European business, Other revenues.
Where can I find the official investor relations documents of BioCryst Pharmaceuticals?
NadirAlpha links all 52 original filings used (SEC filings) in the sources chapter: quarterly report, earnings release, annual report, each with type, publication date and a direct link; every figure in the report carries a source number.